Jan Kaiserle

The development of cyclic peptides like FAP-2286 underscores the potential of fibroblast activation protein as a versatile pan-cancer target for molecular imaging. This approach has catalyzed a movement toward a more nuanced understanding of how radioactive isotopes can be harnessed to identify and

The Neonatal Fc receptor has emerged as a high-value target in immunology because it plays a critical role in recycling the antibodies that sustain autoimmune activity. This shift toward complex, target-specific medicine is forcing the global pharmaceutical infrastructure to evolve beyond simple

The shift toward non-invasive kinetic quantification allows clinicians to measure tracer behavior without the logistical burdens and patient discomfort associated with manual blood sampling. In the current medical landscape of 2026, the widespread adoption of Long Axial Field of View (LAFOV)

Vertex Pharmaceuticals says its commercial team is ready for povetacicept, a prospective treatment for IgA nephropathy that could receive Food and Drug Administration approval by the end of the month. That readiness brings the company’s kidney strategy closer to patient care, where the eventual

The primary bottleneck in modern medicine is no longer the discovery of molecules but the ability to accurately predict which interventions will work for specific diseases. For decades, the pharmaceutical sector has operated under a paradigm that prioritized the synthesis of novel chemical

Any project seeking to increase the virulence or transmissibility of a biological agent faces immediate federal funding restrictions under the strict definitions of the new Stopping Policy guidelines. This regulatory pivot, formalized in mid-2026, marks the end of an era where oversight was

Struggling mental health services have emerged as a surprising yet critical factor in the high rates of cancer-related deaths across various American counties. This revelation stems from a significant research initiative led by Northern Illinois University which moved to identify the geographical

The global medical supply chain relies heavily on Indian manufacturing, making any shift in domestic pharmaceutical regulations a matter of international concern for healthcare providers and patients alike. The Ministry of Health recently proposed rigorous amendments to the Drugs Rules, signaling a

Kiji Therapeutics is developing gene-engineered, iPSC-derived MSCs, an approach that Miguel Forte, M.D., Ph.D., CEO and Co-Founder of Kiji Therapeutics and immediate past president of ISCT, described as a way to establish more consistent starting material. Its manufacturing strategy illustrates a

Patients receiving Roche’s divarasib lived a median of roughly 18 months in a Phase 3 lung cancer trial, compared with about 12 months among those receiving Krazati or Lumakras. That finding, presented at the European Society for Medical Oncology meeting, sits alongside encouraging results for a